archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Mix2Vial™
    and filtering The Mix2Vial is a double ended all plastic filter transfer set optimally designed for use with CSL Behring s range of freeze dried plasma derived therapeutics Products prepared with Mix2Vial BIOSTATE MonoFIX VF PROTHROMBINEX VF THROMBOTROL VF Easy2Use Facilitates fast and simple reconstitution Easy2Identify Blue adaptor for water For use with Water for Injections in glass vials Convenient All plastic construction design reduces chance of needle stick injury

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562673365/Web_Product_C/1196562715848/ProductDetail.htm (2014-01-05)
    Open archived version from archive


  • Mix2Vial™
    filter transfer set for enhanced ease of reconstitution and filtering The Mix2Vial is a double ended all plastic filter transfer set optimally designed for use with CSL Behring s range of freeze dried plasma derived therapeutics Products prepared with Mix2Vial BIOSTATE PROTHROMBINEX VF Easy2Use Facilitates fast and simple reconstitution Easy2Identify Blue adaptor for water For use with Water for Injections in glass vials Convenient All plastic construction design reduces chance

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562765747/Web_Product_C/1196562734297/ProductDetail.htm (2014-01-05)
    Open archived version from archive

  • Mix2Vial™
    Kong Mix2Vial filter transfer set for enhanced ease of reconstitution and filtering The Mix2Vial is a double ended all plastic filter transfer set optimally designed for use with CSL Behring s range of freeze dried plasma derived therapeutics Products prepared with Mix2Vial BIOSTATE PROTHROMBINEX HT Easy2Use Facilitates fast and simple reconstitution Easy2Identify Blue adaptor for water For use with Water for Injections in glass vials Convenient All plastic construction design

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562765747/Web_Product_C/1196562738353/ProductDetail.htm (2014-01-05)
    Open archived version from archive

  • Mix2Vial™
    enhanced ease of reconstitution and filtering The Mix2Vial is a double ended all plastic filter transfer set optimally designed for use with CSL Behring s range of freeze dried plasma derived therapeutics Products prepared with Mix2Vial BIOSTATE MonoFIX VF PROTHROMBINEX VF THROMBOTROL VF Easy2Use Facilitates fast and simple reconstitution Easy2Identify Blue adaptor for water For use with Water for Injections in glass vials Convenient All plastic construction design reduces chance

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562765747/Web_Product_C/1196562733149/ProductDetail.htm (2014-01-05)
    Open archived version from archive

  • Mix2Vial™
    transfer set for enhanced ease of reconstitution and filtering The Mix2Vial is a double ended all plastic filter transfer set optimally designed for use with CSL Behring s range of freeze dried plasma derived therapeutics Products prepared with Mix2Vial BIOSTATE Easy2Use Facilitates fast and simple reconstitution Easy2Identify Blue adaptor for water For use with Water for Injections in glass vials Convenient All plastic construction design reduces chance of needle stick

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562765747/Web_Product_C/1199979207607/ProductDetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited and their involvement in clinical trials.
    the laboratory and in animals Clinical trials are carefully supervised monitored and documented The applicable regulatory authority must grant approval to conduct testing in humans and clinical trials are overseen by an independent review body How are clinical trials conducted CSL conducts clinical trials in accordance with the current Guideline for Good Clinical Practice GCP of the International Conference on Harmonisation ICH GCP is an international ethical and scientific quality standard for designing conducting and reporting studies that involve the participation of human subjects Compliance with this standard provides public assurance that the rights safety and well being of study subjects are protected and that the clinical trial data are credible Compliance with this standard also ensures that CSL conducts clinical trials consistent with the principles that have originated in the Declaration of Helsinki Current Studies All Bleeding Disorders Critical Care Immunoglobulins Pulmonary Therapeutic Proteins Vaccines Wound Healing Condition Additional Trial Information Congenital Fibrinogen Deficiency Fibrinogen Concentrate Human Efficacy and Safety Study Learn More Leukemia Myeloid Acute A Study of CSL362 in Patients With CD123 Acute Myeloid Leukemia Currently in Remission Learn More Emphysema Caused by API Deficiency Study of Zemaira i v Administration in Subjects Who Completed a 2 Year Controlled Study With This Treatment and Have Emphysema Due to alpha1 Proteinase Inhibitor Deficiency Learn More Hemophilia A An Open label Safety Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A Learn More Hemophilia A Study of a Plasma Derived von Willebrand Factor Factor VIII Concentrate vWF FVIII Biostate in Subjects with Hemophilia A Learn More Page 1 of 3 Next Last Trial Phases Following a positive outcome in preclinical testing the sponsoring organisation usually a drug manufacturer will seek approval to conduct clinical trials Once approval has

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649386/page/1255926192818/TabsLandingPage.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited and their involvement in clinical trials.
    it is first tested extensively in the laboratory and in animals Clinical trials are carefully supervised monitored and documented The applicable regulatory authority must grant approval to conduct testing in humans and clinical trials are overseen by an independent review body How are clinical trials conducted CSL conducts clinical trials in accordance with the current Guideline for Good Clinical Practice GCP of the International Conference on Harmonisation ICH GCP is an international ethical and scientific quality standard for designing conducting and reporting studies that involve the participation of human subjects Compliance with this standard provides public assurance that the rights safety and well being of study subjects are protected and that the clinical trial data are credible Compliance with this standard also ensures that CSL conducts clinical trials consistent with the principles that have originated in the Declaration of Helsinki Current Studies All Bleeding Disorders Critical Care Immunoglobulins Pulmonary Therapeutic Proteins Vaccines Wound Healing Condition Additional Trial Information Hemophilia B A Safety Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin rIX FP in Children With Hemophilia B Learn More Hemophilia B A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin rIX FP in Patients With Hemophilia B Learn More Hereditary Angioedema HAE Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Learn More Surgical Blood Loss Postoperative Blood Loss Study of Fibrinogen Concentrate Human FCH to Control Bleeding During Complex Cardiovascular Surgery REPLACE Learn More Von Willebrand Disease Extension Study of Biostate in Subjects with Von Willebrand Disease Learn More Page 2 of 2 First Trial Phases Following a positive outcome in preclinical testing the sponsoring organisation usually a drug manufacturer will seek approval to conduct clinical trials Once approval has been granted the sponsor will

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649386/page/1255926192841/TabsLandingPage.htm?currentPage=2 (2014-01-05)
    Open archived version from archive

  • Archived ASX Releases 2008 - 2012
    CSL shares More 17 08 2011 Full Year Results Announcement for 2010 11 CSL Limited today reported a net profit after tax of 941 million for the twelve months ended 30 June 2011 down 112 million or 11 when compared to the prior comparable period More 17 08 2011 CSL Announces Changes to the Board CSL Limited ASX CSL today announced that Chairman Miss Elizabeth Alexander AM and Director Mr David Simpson have indicated their intention to retire from the CSL Board of Directors at the conclusion of the Company s Annual General Meeting on 19 October 2011 More 22 06 2011 CSL Biotherapies Statement on FDA Warning Letter for GMP issues at Australian Influenza Vaccine Facility Today the US Food and Drug Administration FDA published a Warning Letter issued by its Office of Compliance and Biologics Quality to CSL Biotherapies a division of CSL Limited The FDA regulates the manufacture marketing and distribution of CSL Biotherapies influenza vaccine Afluria in the US market More 20 05 2011 Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference CSL Limited ASX CSL subsidiary CSL Behring today issued a press release regarding advances that it is making in developing

    Original URL path: http://www.csl.com.au/investors/archived-asx-releases.htm (2014-01-05)
    Open archived version from archive